Evidence map›Paper›PMID 26877601›Full record

ReviewWorld journal of gastroenterology2016

Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Roberto Iezzi, Maurizio Pompili, Alessandro Posa, Giuseppe Coppola, Antonio Gasbarrini, Lorenzo Bonomo

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Sorafenib with or without co-interventions for hepatocellular carcinoma.The Cochrane database of systematic reviews · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Roberto IezziRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Maurizio PompiliRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Alessandro PosaRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Giuseppe CoppolaRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Antonio GasbarriniRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Lorenzo BonomoRoberto Iezzi, Alessandro Posa, Giuseppe Coppola, Lorenzo Bonomo, Department of Bioimaging, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, 00168 Rome, Italy.
Agostino Gemelli University Polyclinic · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma (HCC). One such combined strategy is based on the combination of the percutaneous approach, such as radiofrequency ablation (RFA), and the intra-arterial locoregional approach, such as trans-arterial chemoembolization (TACE). Several types of evidence have supported the feasibility and benefit of combined therapy, despite some studies reporting conflicting results and outcomes. The aim of this review was to explain the technical aspects of different combined treatments and to comprehensively analyze and compare the clinical efficacy and safety of this combined treatment option and monotherapy, either as TACE or RFA alone, in order to provide clinicians with an unbiased opinion and valuable information. Based on a literature review and our experience, combined treatment seems to be a safe and effective option in the treatment of patients with early/intermediate HCC when surgical resection is not feasible; furthermore, this approach provides better results than RFA and TACE alone for the treatment of large HCC, defined as those exceeding 3 cm in size. It can also expand the indication for RFA to previously contraindicated "complex cases", with increased risk of thermal ablation related complications due to tumor location, or to "complex patients" with high bleeding risk.

Indexed as

Catheter AblationCarcinoma, HepatocellularChemoembolization, TherapeuticChemotherapy, AdjuvantHumansLiver NeoplasmsRisk FactorsTime FactorsTreatment OutcomeAblationChemoembolizationCombined treatmentHepatocellular carcinomaMicrowave

Identifiers

PMID26877601
PMCPMC4726669
OpenAlexW2401804267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.